Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 93Terminated 36Unknown 12Withdrawn 4Active not recruiting 3Recruiting 2Suspended 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Recurrence 2Lymphoma, B-Cell 1Burkitt Lymphoma 1

Interventions

pembrolizumab 551Specimen Handling 465Carboplatin 441Magnetic Resonance Spectroscopy 430Cyclophosphamide 412Cisplatin 397Radiotherapy 313Gemcitabine 309Bevacizumab 307Paclitaxel 294Biopsy 261Drug Therapy 249Capecitabine 242Oxaliplatin 239fludarabine 237Nivolumab 224venetoclax 219Injections 213Docetaxel 205Fluorouracil 203Dexamethasone 187Radiosurgery 172Rituximab 158Pemetrexed 153Standard of Care 146durvalumab 143Leucovorin 139atezolizumab 138toripalimab 134tislelizumab 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Interventional × Alemtuzumab × Clear all
NCT04150497 2025-09-09

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Cellectis S.A.

Phase 1/2 Recruiting
52 enrolled
Lymphoid

Burkitt Lymphoma, Recurrence

NCT05607420 2025-08-24

NatHaLi-01

Cellectis S.A.

Phase 1/2 Recruiting
80 enrolled
Lymphoid

Recurrence, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡